Biomedical Nanotechnology for Cancer

Medical Clinics of North America

Volumn 91, Issue 5, 2007, Pages 899-927

  Pope Harman, Amy ^a   Cheng, Mark Ming Cheng ^b,c   Robertson, Fredika ^d   Sakamoto, Jason ^b,e   Ferrari, Mauro ^b,c,d,e,f  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Alliance for NanoHealth   (United States)

^f Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANCICLOVIR; IRON OXIDE; LIPOSOME; LURTOTECAN; MUCIN 1; NANOPARTICLE; SINGLE STRANDED DNA; TRASTUZUMAB; VINCRISTINE;

CANCER CYTODIAGNOSIS; CANCER THERAPY; DIAGNOSTIC APPROACH ROUTE; DNA HYBRIDIZATION; DNA STRUCTURE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; EARLY DIAGNOSIS; ELECTRON SPIN RESONANCE; HEALTH STATUS; HUMAN; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; MAGNETIC FIELD; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; NANOENGINEERING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STRUCTURE; PROTEOMICS; RADIOFREQUENCY ABLATION; RADIOFREQUENCY RADIATION; REVIEW; STRUCTURE ANALYSIS; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; PROGNOSIS;

EID: 34548419696     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.05.008     Document Type: Review

References (136)

1. Hood L., Heath J.R., Phelps M.E., et al. Systems biology and new technologies enable predictive and preventative medicine. Science 306 (2004) 640-643
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5 (2005) 161-171
3. Jin E., Fujiwara M., Nagashima M., et al. Aerogenous spread of primary lung adenocarcinoma induces ultrastructural remodeling of the alveolar capillary endothelium. Hum Pathol 32 10 (2001) 1050-1058
4. Palmisano W.A., Divine K.K., Saccomanno G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60 21 (2000) 5954-5958
5. Belinsky S.A., Nikula K.J., Palmisano W.A., et al. Methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 95 20 (1998) 11891-11896
6. Ottey M., Han S.Y., Druck T., et al. FHIT-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 91 9 (2004) 1669-1677
7. Ishii H., Dumon K.R., Vecchione A., et al. CM: potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA 286 19 (2001) 2441-2449
8. Wright M.E., Han D.K., and Aebersold R. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol Cell Proteomics 4 (2005) 545-554
9. Pan S., Zhang H., Rush J., et al. High throughput proteome screening for biomarker detection. Mol Cell Proteomics 4 (2005) 182-190
10. Stoeckli M., Chaurand P., Hallahan D.E., et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7 (2001) 493-496
11. Liotta L.A., Ferrari M., and Petricoin E. Clinical proteomics: written in blood. Nature 425 (2003) 905
12. Terracciano R, Gaspari M, Testa F, et al. Selective binding and enrichment for low molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics 2006;6(11):3243-50.
13. Gaspari M, Cheng MC, Terracciano R, et al. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. Journal of Proteomic Research 2006;5(5):1261-6.
14. Liotta L.A., Espina V., Mehta A.I., et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3 (2003) 317-325
15. Geho D., Lahar N., Cheng M.M.C., et al. Pegylated, streptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. Bioconjug Chem 17 3 (2006) 654-661
16. Nijdam AJ, Cheng MC, Geho DH, et al. Physicochemically modified silicon as candidate substrate for protein microarrays. Biomaterials 2007;28(3):550-8.
17. Nam J.-M., Thaxton C.S., and Mirkin C.A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301 (2003) 1884-1886
18. Nam J.-M., Park S.-J., and Mirkin C.A. Bio-barcodes based on oligonucleotide-modified nanoparticles. Journal of the American Chemical Society 124 (2002) 3820-3821
19. Nam J.-M., Stoeva S.I., and Mirkin C.A. Bio-bar-code-based DNA detection with PCR-like sensitivity. J Am Chem Soc 126 (2004) 5932-5933
20. Thaxton C.S., Hill H.D., Georganopoulou D.G., et al. A bio-bar-code assay based upon dithiothreitol-induced oligonucleotide release. Anal Chem 77 24 (2005) 8174-8178
21. Georganopoulou D.G., Chang L., Nam J.-M., et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102 (2005) 2273-2276
22. Mirkin C.A., Letsinger R.L., Mucic R.C., et al. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 382 (1996) 607-609
23. Elghanian R., Storhoff J.J., Mucic R.C., et al. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 277 (1997) 1078-1080
24. Park S.J., Taton T.A., and Mirkin C.A. Array-based electrical detection of DNA with nanoparticle probes. Science 295 (2002) 1503-1506
25. Katz E., and Willner I. Biomolecule-functionalized carbon nanotubes: applications in nanobioelectronics. Chemphyschem 5 8 (2004) 1084-1104
26. Davis J.J., Coleman K.S., Azamian B.R., et al. Chemical and biochemical sensing with modified single walled carbon nanotubes. Chemistry 9 16 (2003) 3732-3739
27. Hahm J.-I., and Lieber C.M. Direct ultrasensitive electrical detection of DNA and DNA sequence variations using nanowire nanosensors. Nano Lett 4 (2004) 51-54
28. Vieu C., Carcenac F., Pepin A., et al. Electron beam lithography: resolution limits and applications. Applied Surface Science 164 (2000) 111-117
29. Yousaf M.N., Mrksich M., and Diels-Alder. Reaction for the selective immobilization of protein to electroactive self-assembled monolayers. J Am Chem Soc 121 (1999) 4286-4287
30. Bunimovich Y.L., Ge G., Beverly K.C., et al. Electrochemically programmed, spatially selective biofunctionalization of silicon wires. Langmuir 20 (2004) 10630-10638
31. Thundat T., and Majumdar A. Microcantilevers for physical, chemical, and biological sensing. In: Barth F.G., Humphrey J.A.C., and Seecomb T.W. (Eds). Sensors and sensing in biology and engineering (2003), Springer-Verlag, New York 338-355
32. Ziegler C. Cantilever-based biosensors. Anal Bioanal Chem 379 (2004) 946-959
33. Lee J.H., Hwang K.S., Park J., et al. Immunoassay of prostate-specific antigen (PSA) using resonant frequency shift of piezoelectric nanomechanical microcantilever. Biosens Bioelectron 20 (2005) 2157-2162
34. Mukhopadhyay R., Lorentzen M., Kjems J., et al. Nanomechanical sensing of DNA sequences using piezoresistive cantilevers. Langmuir 21 (2005) 8400-8408
35. Alvarez M., Carrascosa L.G., Moreno M., et al. Nanomechanics of the formation of DNA self-assembled monolayers and hybridization on microcantilevers. Langmuir 20 (2004) 9663-9668
36. Weeks B.L., Camarero J., Noy A., et al. A microcantilever-based pathogen detector. Scanning 25 (2003) 297-299
37. Ji H.F., Yang X., Zhang J., et al. Molecular recognition of biowarfare agents using micromechanical sensors. Expert Rev Mol Diagn 4 (2004) 859-866
38. Ketai L.H., Muggenberg B.A., McIntire G.L., et al. CT imaging of intrathoracic lymph nodes in dogs with bronchoscopically administered iodinated nanoparticles. Acad Radiol 6 1 (1999) 49-54
39. Won J., Kim M., Yi Y.W., et al. A magnetic nanoprobe technology for detecting molecular interactions in live cells. Science 309 5731 (2005) 121-125
40. Zhang Y., Kohler N., and Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23 7 (2002) 1553-1561
41. Costouros N.G., Lorang D., Zhang Y., et al. Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. Mol Imaging 1 3 (2002) 301-308
42. Ilangovan G., Bratasz A., and Li H. In vivo measurement and imaging of tumor oxygenation using coembedded paramagnetic particulates. Magn Reson Med 52 3 (2004) 650-657
43. Crowther J.E., Kutala V.K., Kuppusamy P., et al. Pulmonary surfactant protein inhibits macrophage reactive oxygen intermediate production in response to stimuli by reducing NADPH oxidase activity. J Immunol 172 11 (2004) 6866-6874
44. Daniel M.C., Ruiz J., Nlate S., et al. Nanoscopic assemblies between supramolecular redox active metallodendrons and gold nanoparticles: synthesis, characterization, and selective recognition of H2PO4-, HSO4-, and adenosine-5'-triphosphate (ATP2-) anions. J Am Chem Soc 125 9 (2003) 2617-2628
45. Liu J., and Ferrari M. Mechanical spectral signatures of malignant disease? A small-sample, comparative study of continuum vs. nano-biomechanical data analyses. Dis Markers 18 4 (2002) 175-183
46. Sakamoto J.H., Smith B.R., Xie B., et al. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents. Technol Cancer Res Treat 4 6 (2005) 627-636
47. Sakamoto JH, Smith BR, Ullery Q, et al. C-scan ultrasound quantitative tissue diagnostic method utilizing tumor targeted iron oxide nanoparticle contrast agent for breast cancer biopsy evaluation (manuscript in preparation).
48. Rodriguez O., Fricke S., Chien C., et al. Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle 5 1 (2006) 113-119
49. Zhou J., Leuschner C., Kumar C., et al. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases. Biomaterials 27 9 (2006) 2001-2008
50. Lemke A.J., Senfft von Pilsach M.I., Lubbe A., et al. MRI after magnetic drug targeting in patients with advanced solid malignant tumors. Eur Radiol 14 11 (2004) 1949-1955
51. Merkle E.M., Goldberg S.N., and Boll D.T. Effects of superparamagnetic iron oxide on radio-frequency-induced temperature distribution: in vitro measurements in polyacrylamide phantoms and in vivo results in a rabbit liver model. Radiology 212 2 (1999) 459-466
52. Hilger I., Hiergeist R., Hergt R., et al. Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Invest Radiol 37 10 (2002) 580-586
53. DeNardo S.J., DeNardo G.L., Miers L.A., et al. Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 11 19 Pt 2 (2005) 7087s-7092s
54. Oyewumi M.O., Yokel R.A., Jay M., et al. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 95 3 (2004) 613-626
55. Sullivan D.C., and Ferrari M. Nanotechology and tumor imaging. Mol Imaging 3 4 (2004) 364-369
56. Akerman M.E., Chan W.C., Laakkonen P., et al. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 99 20 (2002) 12617-12621
57. Michalet X., Pinaud F.F., Bentolila L.A., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307 5709 (2005) 538-544
58. Huh Y.M., Jun Y.W., Song H.T., et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 27 35 (2005) 12387-12391
59. Martin FJ, Ferrari M, Dehlinger PJ, et al. Particles for oral delivery of peptides and proteins. US Patent No. 6,355,270, March 12, 2002.
60. Stikeman A. The programmable pill. MITS Technol Rev (May 2001) 78-82
61. Kersten G., and Hirschberg H. Antigen delivery systems. Expert Rev Vaccines 3 4 (2004) 453-462
62. Kruse W., Eggert-Kruse W., Rampmaier J., et al. Dosage frequency and drug-compliance behaviour-a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol 41 6 (1991) 589-592
63. Lesinski G.B., Sharma S., Varker K.A., et al. Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed Microdevices 1 (2005) 71-79
64. Ferrari M. Therapeutic microdevices and methods of making and using same. U.S. Patent No. 6,107,102, August 22, 2000.
65. Decuzzi P., Lee S., Decuzzi M., et al. Adhesion of microfabricated particles on vascular endothelium: a parametric analysis. Ann Biomed Eng 32 6 (2004) 793-802
66. Khanna C., Anderson P.M., Hasz D.E., et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79 7 (1997) 1409-1421
67. Skubitz K.M., and Anderson P.M. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 11 7 (2000) 555-563
68. Numico G., Castiglione F., Granetto C., et al. Single-agent pegylated liposomal doxorubicin (Caelix(R)) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer 35 1 (2002) 59-64
69. Kim E.S., Lu C., Khuri F.R., et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34 3 (2001) 427-432
70. Booser D.J., Esteva F.J., Rivera E., et al. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 35 1 (2002) 59-64
71. Verschraegen C.F., Gilbert B.E., Loyer E., et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10 (2004) 2319-2326
72. Goldbach P., Dumont S., Kessler R., et al. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. Am J Physiol 270 3 Pt 1 (1996) L429-L434
73. Kurohane K., Namba Y., and Oku N. Liposomes modified with a synthetic Arg-Gly-Asp mimetic inhibit lung metastasis of B16BL6 melanoma cells. Life Sci 68 3 (2000) 273-281
74. Asai T., Shuto S., Matsuda A., et al. Targeting and anti-tumor efficacy of lipsomal 5-O-dipalmitoylphosphatidyl 2- C-cyano-2-deoxy-1-d-arabino-pentofuranosylcytosine in mice lung bearing B16BL16 melanoma. Cancer Lett 8 (2001) 49-56
75. Maillard S., Ameller T., Gauduchon J., et al. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol 94 1-3 (2005) 111-121
76. Park J.W., Benz C.C., and Martin F.J. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31 6 Suppl 13 (2004) 196-205
77. Sugano M., Egilmez N.K., Yokota S.J., et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60 24 (2000) 6942-6949
78. Drummond D.C., Meyer O., Hong K., et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51 4 (1999) 691-743
79. Park J.W., Kirpotin D.B., Hong K., et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release 74 1-3 (2001) 95-113
80. Park J.W., Hong K., Kirpotin D.B., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8 4 (2002) 1172-1181
81. Peer D., and Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6 4 (2004) 343-353
82. Harivardhan R.L., Sharma R.K., Chuttani K., et al. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 105 3 (2005) 185-198
83. Tam P., Monck M., Lee D., et al. Stabilized plasmid- lipid particles for systemic gene therapy. Gene Ther 7 21 (2000) 1867-1874
84. Ito I., Began G., Mohiuddin I., et al. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther 7 3 (2003) 409-418
85. Ito I, Saeki T, Mohuiddin I, et al. Persistent transgene expression following intravenous administration of a liposomal complex: role of interleukin-10-mediated immune suppression 2004; 9(3):318-27.
86. Zou Y., Zong G., Ling Y.H., et al. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther 7 5 (2000) 683-696
87. Ramesh R., Saeki T., Templeton N.S., et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 3 3 (2001) 337-350
88. Xu L., Tang W.H., Huang C.C., et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 7 10 (2001) 723-734
89. Zou Y., Peng H., Zhou B., et al. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res 62 (2002) 8-12
90. Ito I., Ji L., Tanaka F., et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11 11 (2004) 733-739
91. Dutour A., Monteil J., Paraf F., et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 11 2 (2005) 311-319
92. Epperly M.W., Sikora C., Defilippi S., et al. Plasmid/liposome transfer of the human manganese superoxide dismutase transgene prevents ionizing irradiation-induced apoptosis in human esophagus organ explant culture. Int J Cancer 90 3 (2000) 128-137
93. Greenberger J.S., Epperly M., Lukeich J., et al. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy protection of the esophagus from chemoradiotherapy damage during treatment of locally unresectable non-small-cell lung cancer (NSCLC). Clin Lung Cancer 1 4 (2000) 302-304
94. Epperly M.W., Defilippi S., Sikora C., et al. Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 7 12 (2000) 1011-1018
95. Pirollo K.F., Zon G., Rait A., et al. Tumor-targeting nanoimmunoliposome complex for short interfering rna delivery. Hum Gene Ther 17 1 (2006) 117-124
96. Yu W., Pirollo K.F., Yu B., et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 32 5 (2004) e48
97. Whitmore M.M., Li S., Falo Jr. L., et al. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 50 10 (2001) 503-514
98. Dow S., Elmslie R., Kurzman I., et al. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 16 8 (2005) 937-946
99. Karara A.L., Bumaschny, Fiszman G.L., et al. Lipofection of early passages of cell cultures derived from murine adenocarcinomas: in vitro and ex vivo testing of the thymidine kinase/ganciclovir system. Cancer Gene Ther 9 1 (2002) 96-99
100. Sacco M.G., Soldati S., Indraccolo S., et al. Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther 10 (2003) 1903-1909
101. Sakurai F., Terada T., Maruyama M., et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther 10 9 (2003) 661-668
102. Mewani R.R., Tang W., Rahman A., et al. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Int J Oncol 24 5 (2004) 1181-1188
103. Stabile L.P., Lyker J.S., Huang L., et al. Inhibition of human non-small cell lung tumors by a c-Met antisenseU6 expression plasmid strategy. Gene Ther 11 3 (2004) 325-335
104. Shen C., Buck A., Polat B., et al. Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer Gene Ther 10 5 (2003) 403-410
105. Gautam A., Waldrep J.C., Densmore C., et al. Aerosol delivery of PEI: p53 in combination with aerosol liposomal 9-N-camptothecin inhibits B16-F10 lung metastases in mice. Gene Ther 9 (2002) 353
106. Pakunlu R.I., Wang Y., Tsao W., et al. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 64 17 (2004) 6214-6224
107. Pan G., Shawer M., Øie S., et al. In vitro gene transfection in human glioma cells using a novel and less cytotoxic artificial lipoprotein delivery system. Pharm Res 20 5 (2003) 738-744
108. Sengupta S., Eavarone D., Capila I., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436 (2005) 568-572
109. Gaber M.H., Wu N.Z., Hong K., et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 36 5 (1996) 1177-1187
110. Shimose S., Sugita T., Nitta Y., et al. Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma. Int J Oncol 19 3 (2001) 585-589
111. Nobuto H., Sugita T., Kubo T., et al. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer 109 4 (2004) 627-635
112. Zhao F., Yin Y., Lu W.W., et al. Preparation and histological evaluation of biomimetic three-dimensional hydroxyapatite/chitosan-gelatin network composite scaffolds. Biomaterials 23 15 (2002) 3227-3234
113. Roser M., Fischer D., and Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 46 3 (1998) 255-263
114. Arbos P., Campanero M.A., Arangoa M.A., et al. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J Control Release 96 1 (2004) 55-65
115. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53 2 (2001) 283-318
116. Matsumura Y., Hamaguchi T., Ura T., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91 10 (2004) 1775-1781
117. Gordon E.M., and Hall F.L. Nanotechnology blooms, at last. Oncol Rep 13 6 (2005) 1003-1007
118. Kang B.K., Chon S.K., Kim S.H., et al. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm 286 1-2 (2004) 147-156
119. Ameller T., Marsaud V., Legrand P., et al. In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668. Int J Cancer 103 6 (2003) 426-454
120. Sharma A., Harper C.M., Hammer L., et al. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiopharm 19 6 (2004) 764-769
121. Nigavekar S.S., Sung L.Y., Llanes M., et al. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 21 3 (2004) 476-483
122. Cortez-Retamozo V., Backmann N., Senter P.D., et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64 (2004) 2853-2857
123. McDevitt M.R., Ma D., Lai L.T., et al. Tumor Therapy with targeted atomic nanogenerators. Science 294 (2001) 1527-1540
124. Prabha S., and Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res 21 2 (2004) 354-364
125. Lambert G., Bertrand J.R., Fattal E., et al. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 279 2 (2000) 401-406
126. Bourdon O., Laville I., Carrez D., et al. Biodistribution of meta-tetra(hydroxyphenyl)chlorin incorporated into surface-modified nanocapsules in tumor-bearing mice. Photochem Photobiol Sci 1 9 (2002) 709-714
127. Larina I.V., Evers B.M., Ashitkov T.V., et al. Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation. Technol Cancer Res Treat 4 2 (2005) 217-226
128. Lo C.L., Lin K.M., and Hsiue G.H. Preparation and characterization of intelligent core-shell nanoparticles based on poly(D,L-lactide)-g-poly(N-isopropyl acrylamide-co-methacrylic acid. J Control Release 104 3 (2005) 477-488
129. Ai H., Pink J., Shuai X., et al. Interactions between self-assembled polyelectrolyte shells and tumor cells. J Biomed Mater Res 73A 3 (2005) 303-312
130. Butts C., Murray N., Maksymiuk A., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23 27 (2005) 6674-6681
131. Asada H., Kishida T., Hirai H., et al. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 5 pt1 (2002) 609
132. Krishnan L., Sad S., Patel G.B., et al. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 63 10 (2003) 2526-2534
133. Hamad-Schifferli K., Schwartz J., Santos A.T., et al. Remote electronic control of DNA hybridization through inductive coupling to an attached metal nanocrystal antenna. Nature 415 (2002) 152-155
134. Iacob G.H., Rotariu O., Strachan N.J., et al. Magnetizable needles and wires-modeling an efficient way to target magnetic microspheres in vivo. Biorheology 41 5 (2004) 599-612
135. Sun Q., Wang Q., Rao B.K., et al. Electronic structure and bonding of Au on a SiO2 cluster: a nanobullet for tumors. Phys Rev Lett 93 (2004) 186803
136. Lin A.W., Lewinski N.A., West J.L., et al. Optically tunable nanoparticle contrast agents for early cancer detection: model-based analysis of gold nanoshells. J Biomed Opt 10 6 (2005) 64035